Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial

European Urology 2026

View at publisher

Authors: Peter E. Clark

DOI: 10.1016/j.eururo.2026.02.006

Cited by: 0

References: 2

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary Bladder and Prostate Research

References 2